VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Wednesday, January 7, 2026
Stock Comparison
AstraZeneca PLC vs Boston Scientific Corporation
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
AstraZeneca PLC
AZN · London Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.
View AZN analysisBoston Scientific Corporation
BSX · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Boston Scientific Corporation's moat claims, evidence, and risks.
View BSX analysisComparison highlights
- Moat score gap: AstraZeneca PLC leads (71 / 100 vs 65 / 100 for Boston Scientific Corporation).
- Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Boston Scientific Corporation has 5 segments (49.8% in Cardiology).
- Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
- Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Boston Scientific Corporation has 6 across 3.
Primary market context
AstraZeneca PLC
Oncology
Innovator oncology therapeutics (branded prescription medicines)
Global
Hospitals, oncology clinics, payers
Innovator biopharmaceutical company
41%
Boston Scientific Corporation
Cardiology
Cardiology devices (interventional cardiology, structural heart, electrophysiology, cardiac rhythm management and remote monitoring)
Global
Hospitals/cath labs/EP labs and specialty clinics (cardiologists, electrophysiologists)
Medical device OEM / implantables + procedure devices + service-enabled monitoring
49.8%
Side-by-side metrics
Moat coverage
Shared moat types
AstraZeneca PLC strengths
Boston Scientific Corporation strengths
Segment mix
AstraZeneca PLC segments
Full profile >Oncology
Oligopoly
Cardiovascular, Renal and Metabolism (CVRM)
Competitive
Respiratory & Immunology (R&I)
Oligopoly
Vaccines & Immune Therapies (V&I)
Oligopoly
Rare Disease
Oligopoly
Other Medicines
Competitive
Boston Scientific Corporation segments
Full profile >Endoscopy
Oligopoly
Urology
Competitive
Neuromodulation
Oligopoly
Cardiology
Oligopoly
Peripheral Interventions
Competitive
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.